Device Industry Continues Push To Influence Health Care Reform Dialogue
With comprehensive U.S. health care reform being viewed as a realistic near-term objective among key figures on Capitol Hill, a seat at the decision-making table is perhaps the best any one interest group could hope for - and signs suggest device firms have not been left idly standing
More from Archive
More from Medtech Insight
An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.
TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.
The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.